Bunkerhill ECG-EF vs Eko Low Ejection Fraction Tool (ELEFT)

Bunkerhill ECG-EF (Tool A) integrates seamlessly with existing EHRs and utilizes routine 12-lead ECG data, which is a standard and widely available diagnostic. This software-only approach likely minimizes disruption to current clinical workflows and avoids the need for new hardware procurement. In contrast, Eko Low Ejection Fraction Tool (Tool B) requires integration with Eko digital stethoscopes, potentially introducing an additional hardware requirement and associated training.

Both tools are FDA-cleared AI algorithms designed for the early identification of patients at risk for heart failure by detecting low ejection fraction. Both have published clinical validation studies, with Eko's algorithm validated in a multi-site prospective study and Bunkerhill's in a retrospective study involving a large patient cohort. While they leverage different data inputs (routine 12-lead ECGs for Tool A vs. digital stethoscope ECG and heart sounds for Tool B), both offer significant clinical utility in their respective contexts.

Neither Bunkerhill ECG-EF (Tool A) nor Eko Low Ejection Fraction Tool (Tool B) provides transparent pricing information, both requiring direct contact for quotes. Tool B explicitly states it's part of an 'enterprise solution' (SENSORAu2122 platform), which could imply a bundled offering or higher overall cost, but without specific details, a direct comparison of value is not possible.

Both tools demonstrate strong foundational enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. However, Bunkerhill ECG-EF (Tool A) emphasizes seamless integration with existing EHRs and clinical archives as a software-only solution, which generally simplifies large-scale deployment. Eko Low Ejection Fraction Tool (Tool B), while cloud-based and part of an enterprise platform, requires specific Eko digital stethoscopes, potentially adding complexity to enterprise-wide hardware management and procurement.

While Bunkerhill ECG-EF (Tool A) leverages generative AI for clinical reasoning and action and integrates with existing ECG workflows, Eko Low Ejection Fraction Tool (Tool B) presents a more distinct innovative approach. It integrates AI directly with a digital stethoscope for rapid (approximately 15 seconds) point-of-care screening during routine physical exams, analyzing both ECG and heart sound recordings.

Eko Health (Tool B's company) offers a dedicated 'Support' section on its website, providing FAQs, user manuals, and various contact options for customer experience and technical support. In contrast, Bunkerhill Health (Tool A's company) does not have readily apparent dedicated support portals or extensive public documentation beyond general contact information, making Eko's support infrastructure more robust and accessible.